Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
For more information please visit the Australian prescription medicine decision summaries information page.
Results for
"[search-keyword]"
Search
186 result(s) found, displaying 1 to 25
- AlhemoPrescription medicine decision summaryAlhemo (concizumab) is approved to prevent haemophilia.
- TibsovoPrescription medicine decision summaryTibsovo (ivosidenib) is approved to treat acute myeloid leukaemia that carries an IDH1 R132 mutation.
- VaxchoraPrescription medicine decision summaryVaxchora (vibrio cholerae) is approved to prevent disease caused by Vibrio cholerae serogroup O1 in those travelling to cholera-affected countries.
- XenpozymePrescription medicine decision summaryXenpozyme (olipudase alfa) is approved for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
- ColumviPrescription medicine decision summaryColumvi (glofitamab) is provisionally approved to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Nurtec ODTPrescription medicine decision summaryNurtec ODT (rimegepant (as sulfate)) is approved to treat migraine
- Exarane/Exarane FortePrescription medicine decision summaryExarane (enoxaparin sodium) is approved to prevent and/or treat thromboembolic disorders, angina and non-Q-wave myocardial infarction and ST-segment Elevation Myocardial Infarction.
- TavneosPrescription medicine decision summaryTGA decision: Tavneos (avacopan) is approved to treat adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).
- IdefirixPrescription medicine decision summaryTGA decision: Idefirix (imlifidase) has provisional approval for desensitisation treatment of adult kidney transplant candidates.
- AlhemoPrescription medicine decision summaryTGA decision: Alhemo is approved where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have haemophilia B.
- RetevmoPrescription medicine decision summaryWe have approved Retevmo (selpercatinib) to treat adult patients with Non-Small Cell Lung Cancer (NSCLC).
- AndexxaPrescription medicine decision summaryWe have provisionally approved Andexxa (andexanet alfa) for patients treated with a direct factor Xa inhibitor, when reversal of anticoagulation is needed.
- MinjuviPrescription medicine decision summaryWe have approved Minjuvi (tafasitamab) to treat diffuse large B-cell lymphoma (DLBCL).
- ImjudoPrescription medicine decision summaryThe medicine Imjudo (tremelimumab), in combination with durvalumab, is approved to treat adult patients with unresectable hepatocellular carcinoma (uHCC).
- TecvayliPrescription medicine decision summaryThe medicine Tecvayli (teclistamab) has been approved by the TGA to treat multiple myeloma.
- IntrarosaPrescription medicine decision summaryTGA decision: Intrarosa (prasterone) is approved to treat vulvar and vaginal atrophy in postmenopausal women.
- EsperoctPrescription medicine decision summaryTGA decision: Esperoct (turoctocog alfa pegol) is approved to treat haemophilia A.
- GavretoPrescription medicine decision summaryTGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with advanced or metastatic rearranged during transfection- fusion positive thyroid cancer.
- TibsovoPrescription medicine decision summaryTGA decision: Tibsovo (ivosidenib) is approved to treat cancer.
- Teriparatide Lupin, Teriparatide GH and Teriparatide LAPLPrescription medicine decision summaryTGA decision: Teriparatide Lupin and LAPL and GH (teriparatide acetate) are approved for the treatment of osteoporosis.
- GavretoPrescription medicine decision summaryTGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with locally advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer.
- JiviPrescription medicine decision summaryTGA decision: Jivi (damoctocog alfa pegol) is approved to treat adults and adolescents (12 years of age and older) with haemophilia A
- SunlencaPrescription medicine decision summaryTGA decision: Sunlenca (lenacapavir sodium) is approved to treat multidrug resistant HIV-1 infection.
- RadicavaPrescription medicine decision summaryTGA decision: Radicava (edaravone) is approved to treat adults with a diagnosis of amyotrophic lateral sclerosis.
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Next page Next ›
- Last page Last »